Amgen/UCB's romosozumab writes script for osteoporosis sequel
This article was originally published in Scrip
Amgen and UCB's investigational sclerostin inhibitor, romosozumab, can produce increases in bone mineral density (BMD) significantly greater than those seen with the older osteoporosis treatments Fosamax (alendronate sodium) and Lilly's Forteo/Forsteo (teriparatide), exploratory analyses of Phase II data suggest. One commentator has suggested that as long as Phase III studies translate the early promise into antifracture efficacy and confirm long-term safety, romosozumab may represent "a sequel to the anabolic story" more than a decade after the introduction of teriparatide.
You may also be interested in...
Daiichi Sankyo and AstraZeneca’s ambitions to expand the use of their HER-2 targeted antibody-drug conjugate product beyond breast cancer are looking realizable on the back of new results presented at ASCO, but toxicities remain an issue.
A highly impressive improvement in disease-free survival in ADAURA is set to pitch AstraZeneca’s best-selling product into a new untapped market, early-stage EGFRm NSCLC, reaping a possible $3bn in extra sales.
The largest-ever rise in the number of active R&D companies, particularly in China, helped propel an unprecedented increase in the size of the biopharma pipeline in 2019. Meanwhile, the number of new active substances launched in their first market last year dropped as 2018’s superlative performance gave way to something more usual.